Market: NMS |
Currency:
Address:
📈 ONC Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$361.05
-
Upside/Downside from Analyst Target:
6.40%
-
Broker Call:
59
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
25-50%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for ONC
| Date | Reported EPS |
|---|
| 2025-11-10 | - |
| 2025-08-06 | 0.84 |
| 2025-05-07 | 0.01 |
| 2025-02-27 | -1.43 |
| 2024-11-12 | -1.15 |
| 2024-08-07 | -1.15 |
| 2024-05-08 | -2.41 |
| 2024-02-26 | -3.48 |
| 2023-11-09 | 2.01 |
| 2023-08-02 | -3.64 |
| 2023-05-04 | -3.34 |
| 2023-02-27 | -4.29 |
| 2022-11-09 | -5.39 |
| 2022-08-04 | -5.56 |
| 2022-05-05 | -4.24 |
| 2022-02-25 | -6.16 |
| 2021-11-04 | -4.46 |
| 2021-08-05 | -5.23 |
| 2021-05-06 | 0.69 |
| 2021-02-25 | -5.2 |
| 2020-11-05 | -4.81 |
| 2020-08-06 | -4.31 |
| 2020-05-11 | -4.7 |
| 2020-03-02 | -6.39 |
| 2019-11-12 | -5.11 |
📰 Related News & Research
-
AcroMeta Enters Indonesian Nickel Trading with Strategic Partnership and Option to Acquire South Konawe Concession 1
January 22, 2026
AcroMeta Group Announces Strategic Entry into Indonesian Nickel Trading via Partnership with PT Esa Jaya Labdagati AcroMeta Group Announces Strategic Entry into Indonesian Nickel Trading…
-
Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)
January 17, 2026
Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong…
-
Autagco Ltd. FY2025 Audited Financials: Material Uncertainty on Going Concern, No Dividend Declared
January 13, 2026
Autagco Ltd. FY2025 Financial Analysis: Material Uncertainty Over Going Concern Autagco Ltd., a Singapore-listed investment holding company, has released its audited financial statements for the…
-
Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Drugs, Global Expansion & Key Financials (2025)
January 11, 2026
Baili Pharmaceutical IPO Analysis: Key Details, Financials, Risks, and Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical Hong Kong IPO:…
-
Concord New Energy Group Successfully Achieves Secondary Listing on Singapore Exchange (SGX-ST)
January 6, 2026
Concord New Energy Group Limited: Key Highlights of Successful Secondary Listing on SGX Concord New Energy Group Limited Announces Successful Secondary Listing on Singapore Exchange…
-
Concord New Energy Group Lists on SGX Mainboard, Expanding Global Renewable Energy Presence 1
January 6, 2026
Concord New Energy Group Limited Secondary Listing on SGX: What Investors Need to Know Concord New Energy Group Limited Makes Strategic Secondary Listing on SGX…
-
Concord New Energy Group Announces Expected Singapore Exchange Secondary Listing Date for January 2026 12
January 5, 2026
Key Points for Investors Concord New Energy Group Limited (Stock Code: 182), incorporated in Bermuda and currently listed on the Hong Kong Stock Exchange, has…
-
Manulife US REIT Announces Extension of MRA Concessions and Financial Covenant Relaxations Until 2026
December 23, 2025
Manulife US REIT Receives Key Extensions to MRA Concessions Manulife US REIT Secures Critical Extensions to MRA Concessions—Implications for Investors Summary of Key Announcements Extension…
-
Manulife US REIT Receives Lender Approvals for MRA Concessions and Extension of Financial Covenants to 2026
December 15, 2025
What Shareholders Should Know Price-Sensitive Developments: The extended disposal window and relaxation of financial covenants are significant. They afford the REIT more flexibility and breathing…
-
Sunrise Shares Holdings Ltd. Faces Material Uncertainty on Going Concern for FY2025—No Dividend Details Announced 1
December 4, 2025
Sunrise Shares Holdings Ltd.: Financial Health and Outlook for FY2025 Sunrise Shares Holdings Ltd. (“Sunrise Shares” or “the Company”) has published its audited financial statements…
🔍 View more Reports
